Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (SUPN) Stock Price & Analysis


SUPN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$21.99 - $42.09
Previous Close$26.78
Average Volume (3M)440.61K
Market Cap
Enterprise Value$1.35B
Total Cash (Recent Filing)$200.19M
Total Debt (Recent Filing)$33.84M
Price to Earnings (P/E)69.0
Feb 27, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding54,632,847
10 Day Avg. Volume263,072
30 Day Avg. Volume440,609
Standard Deviation0.11
Financial Highlights & Ratios
Price to Book (P/B)9.85
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)10.60
P/FCF Ratio10.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda11.89
Price Target Upside57.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2




What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $21.99 and its highest was $42.09 in the past 12 months.
    What is Supernus Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Supernus Pharmaceuticals’s upcoming earnings report date?
    Supernus Pharmaceuticals’s upcoming earnings report date is Feb 27, 2024 which is in 81 days.
      How were Supernus Pharmaceuticals’s earnings last quarter?
      Supernus Pharmaceuticals released its earnings results on Nov 08, 2023. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.295.
        Is Supernus Pharmaceuticals overvalued?
        According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Supernus Pharmaceuticals pay dividends?
          Supernus Pharmaceuticals does not currently pay dividends.
          What is Supernus Pharmaceuticals’s EPS estimate?
          Supernus Pharmaceuticals’s EPS estimate is $0.41.
            How many shares outstanding does Supernus Pharmaceuticals have?
            Supernus Pharmaceuticals has 54,632,847 shares outstanding.
              What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
              Supernus Pharmaceuticals reported an EPS of -$0.29 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went up 11.139%.
                Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
                Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Third Avenue Management LLC. It holds Supernus Pharmaceuticals’s shares valued at 3M.


                  Company Description

                  Supernus Pharmaceuticals

                  Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.


                  Top 5 ETFs holding SUPN

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Vanguard Russell 3000 ETF
                  SPDR S&P 1500 Value Tilt ETF
                  Invesco S&P US Total Market ESG Tilt Index ETF Trust Units -CAD Hedged-
                  Up to five ETFs with an Outperform Smart Score that hold SUPN. The ETFs are listed according to market value of SUPN within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Eagle Pharmaceuticals
                  Heron Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis